3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
228
Neoplasm Metastasis
17
Breast Neoplasms, Male
7
Breast Diseases
7
Neoplasms
6
Carcinoma, Intraductal, Noninfiltrating
4
Recurrence
3
Obesity
3
Breast Carcinoma In Situ
3
Breast Cancer Metastatic
3
Advanced Breast Cancer
3
Neoplasms by Site
2
Bulbo-Spinal Atrophy, X-Linked
2
Arthralgia
2
Vitamin D Deficiency
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Primary Breast Cancer ER+ve
1
Premenopausal Breast Cancer
1
Post Menopausal Women With Early Breast Cancer
1
Patient Acceptance of Health Care
1
Pain
1
Interventions
selpercatinib
2
exemestane
1
entinostat
1
alectinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Respiratory Tract Diseases
×
exemestane
×
Breast
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled